Expression and clinical significance of PAK1 in papillary thyroid carcinoma

doi:10.3877/cma.j.issn.1674-0793.2015.05.007

Abstract

Abstract:

Objective

To investigate the expression of P21 activated kinase 1 (PAK1) protein in papillary thyroid carcinoma (PTC), and to figure out its clinical significance.

Methods

We used strept avidin-biotin complex (SABC), the sensitive immunohistochemistry, to detect the expression of PAK1 in eighty paraffin-embedded specimens, including 55 PTC and 25 benign thyroid nodules, and to explore its relationship with clinicopathological characteristics of PTC.

Results

43.6% of PTC specimens showed significantly higher expression of PAK1 protein than that of benign lesions of thyroid, which had only 8.0% positive expression rate (χ²=9.950, P=0.002). The expression of PAK1 was positively and significantly correlated with tumor invasion, advanced stage and lymph node metastasis (χ²=5.832, P=0.016; χ²=4.448, P=0.035; χ²=4.990, P=0.025), but it had no correlation with age, gender, tumor size, multiple tumors and bilateral tumors in PTC.

Conclusion

The high expression of PAK1 in PTC is related to the possibility of proliferation, invasion and lymph node metastasis.

Key words: Papillary thyroid carcinoma, P21 activated kinase 1, Immunohistochemistry

Qiang Chen, Qingji Xie, Hong Cen, Cong Tang. Expression and clinical significance of PAK1 in papillary thyroid carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2015, 09(05): 356-359.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2015.05.007

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2015/V09/I05/356

Figures/Tables 3

References 18

1	Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973-2002[J]. Cancer Causes Control, 2009, 20(5): 525-531.
2	Dummler B, Ohshiro K, Kumar R, et al. Pak protein kinases and their role in cancer[J]. Cancer Metastasis Rev, 2009, 28(1-2): 51-63.
3	Vadlamudi RK, Kumar R. P21-activated kinases in human cancer[J]. Cancer Metastasis Rev, 2003, 22(4): 385-393.
4	King H, Nicholas NS, Wells CM. Role of p-21-activated kinases in cancer progression[J]. Int Rev Cell Mol Biol, 2014, 309: 347-387.
5	张永海, 谢丹, 罗俊航, 等. 膀胱移行细胞癌中PAK1蛋白表达及其临床意义[J]. 中华医学杂志, 2007, 87(38): 2710-2713.
6	黎志勋, 曾穗德, 刘泳冬, 等. 结直肠癌中P21-激活激酶1基因表达与扩增及其临床病理学意义[J]. 中华胃肠外科杂志, 2009, 12(2): 185-188.
7	何国庆, 管强, 张喜军, 等. 喉癌中PAK1基因mRNA的表达及临床意义[J]. 实用肿瘤学杂志, 2012, 26(5): 410-413.
8	Dammann K, Khare V, Gasche C. Tracing PAKs from GI inflammation to cancer[J]. Gut, 2014, 63(7): 1173-1184.
9	Kumar R, Vadlamudi RK. Emerging functions of p21-activated kinases in human cancer cells[J]. J Cell Physiol, 2002, 193(2): 133-144.
10	谢丹, 杨国奋, 陈玉清, 等. p21-激活激酶1基因在卵巢上皮性肿瘤中的过度表达及其机制和意义[J]. 中华肿瘤杂志, 2006, 28(12): 911-914.
11	Eswaran J, Li DQ, Shah A, et al. Molecular pathways: targeting p21-activated kinase 1 signaling in cancer—opportunities, challenges, and limitations[J]. Clin Cancer Res, 2012, 18(14): 3743-3749.
12	Santarpi L, Lippm SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy[J]. Expert Opin Ther Targets, 2012, 16(1): 103-119.
13	Déléris P, Trost M, Topisirovic I, et al. Activation loop phosphorylation of ERK3/ERK4 by groupⅠ PAKs defines a novel PAK-ERK3/4-MK5 signaling pathway[J]. J Biol Chem, 2011, 286(8): 6470-6478.
14	Menges CW, Sementino E, Talarchek J, et al. Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways[J]. Mol Cancer Res, 2012, 10(9): 1178-1188.
15	Slack-Davis JK, Eblen ST, Zecevic M, et al. PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation[J]. J Cell Biol, 2003, 162(2): 281-291.
16	McCarty SK, Saji M, Zhang X, et al. BRAF activates and physically interacts with PAK to regulate cell motility[J]. Endocr Relat Cancer, 2014, 21(6): 865-877.
17	Li Z, Zou X, Xie L, et al. Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma[J]. PLoS One, 2013, 8(11): e80665.
18	吴况明, 蒋良友. Rac1和Pak1在胃癌中的表达及意义[J]. 国际病理科学与临床杂志, 2010, 30(6): 469-472.

项目		病例数	PAK1表达[例(%)]		χ²值	P值
项目		病例数	高	正常	χ²值	P值
性别		?	?	?	0.253	0.615
?	男	12	6(50.0)	6(50.0)	?	?
?	女	43	18(41.9)	25(58.1)	?	?
年龄(岁)		?	?	?	3.265	0.071
?	<45	39	14(35.9)	25(64.1)	?	?
?	≥45	16	10(62.5)	6(37.5)	?	?
肿瘤大小(cm)		?	?	?	2.289	0.130
?	<2	27	9(33.3)	18(66.7)	?	?
?	≥2	28	15(53.6)	13(46.4)	?	?
是否单发		?	?	?	0.111	0.739
?	单发	40	18((45.0)	22(55.0)	?	?
?	多发	15	6(40.0)	9(60.0)	?	?
是否单侧		?	?	?	0.201	0.733^a
?	单侧	45	19(42.2)	26(57.8)	?	?
?	双侧(含峡部)	10	5(50.0)	5(50.0)	?	?
腺体外浸润		?	?	?	5.832	0.016
?	无	35	11(31.4)	24(68.6)	?	?
?	有	20	13(65.0)	7(35.0)	?	?
临床分期		?	?	?	4.448	0.035
?	Ⅰ、Ⅱ	40	14(35.0)	26(65.0)	?	?
?	Ⅲ、Ⅳ	15	10(66.7)	5(33.3)	?	?
淋巴结转移		?	?	?	4.990	0.025
?	无	30	9(30.0)	21(70.0)	?	?
?	有	25	15(60.0)	10(40.0)	?	?

项目		病例数	PAK1表达[例(%)]		χ²值	P值
项目		病例数	高	正常	χ²值	P值
性别		?	?	?	0.253	0.615
?	男	12	6(50.0)	6(50.0)	?	?
?	女	43	18(41.9)	25(58.1)	?	?
年龄(岁)		?	?	?	3.265	0.071
?	<45	39	14(35.9)	25(64.1)	?	?
?	≥45	16	10(62.5)	6(37.5)	?	?
肿瘤大小(cm)		?	?	?	2.289	0.130
?	<2	27	9(33.3)	18(66.7)	?	?
?	≥2	28	15(53.6)	13(46.4)	?	?
是否单发		?	?	?	0.111	0.739
?	单发	40	18((45.0)	22(55.0)	?	?
?	多发	15	6(40.0)	9(60.0)	?	?
是否单侧		?	?	?	0.201	0.733^a
?	单侧	45	19(42.2)	26(57.8)	?	?
?	双侧(含峡部)	10	5(50.0)	5(50.0)	?	?
腺体外浸润		?	?	?	5.832	0.016
?	无	35	11(31.4)	24(68.6)	?	?
?	有	20	13(65.0)	7(35.0)	?	?
临床分期		?	?	?	4.448	0.035
?	Ⅰ、Ⅱ	40	14(35.0)	26(65.0)	?	?
?	Ⅲ、Ⅳ	15	10(66.7)	5(33.3)	?	?
淋巴结转移		?	?	?	4.990	0.025
?	无	30	9(30.0)	21(70.0)	?	?
?	有	25	15(60.0)	10(40.0)	?	?

[1]	Zhuangzhuang Wu, Xiaojuan Zhang, Zehong Shi, yao Shi, Shaoling Yuan. Prognostic value of ultrasound combined with mammography and PR and HER-2 status in high-grade and middle-low-grade ductal carcinoma in situ of the breast [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(06): 631-635.
[2]	Qiyang Chen, Yujiang Liu, Jinping Liu, Xiaoqu Tan, Linxue Qian, Xiangdong Hu. Diagnostic value of a predictive model based on contrast-enhanced ultrasound for prediction of central cervical lymph node metastasis in patients with thyroid papillary carcinoma [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(04): 442-448.
[3]	Sujuan Li, Wenbo Ding, Xinping Wu, Xuedong Deng. Ultrasound-related risk factors for cervical lymph node metastasis of papillary thyroid microcarcinoma with extracapsular invasion [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(04): 455-461.
[4]	Tingting Cui, Yanyu Li, Qian Wang, Xiaofeng Fu, Gonglin Fan, Li Gao, Lei Xie, Deguang Zhang, Jiang Zhu. Thyroglobulin assessment in needle washout after fine needle aspiration for diagnosis of cervical lymph metastasis of thyroid papillary carcinoma: threshold and efficacy [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(02): 219-226.
[5]	Chunying Han, Tingting Wang, Yanyan Li, Jinxia Piao. Current research status on predictors of lymphatic vascular invasion in patients with endometrial carcinoma [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 403-409.
[6]	Xingchen Liu, Juan Liu, Baobao Wei, Jie Liu, Hui Liu. Correlation analysis of abnormal expression of XIAP and XAF1 with ovarian cancer [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 419-427.
[7]	Yijun Fan, Feng Yang, Wei Wang, Heying Yin, Jun Liu. Research progress in the diagnostic and therapeutic value of Delphian lymph node metastasis in papillary thyroid carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(04): 306-310.
[8]	Yonghao Li, Xuefei Gao, Tiantian Guo, Jin Zhang, Jing Liu. Current status of surgical approaches for papillary thyroid carcinoma of the isthmus [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(03): 225-230.
[9]	Weilin Guo, Yuntao Li, Peizhong Shang, Xiaowu Li, Wei Li. Expression of S100A4 and Midkine in pancreatic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 149-152.
[10]	Junfeng Li, Jun Li, Qinfeng Sun, Jianguang Sun, Xiangxing Kong. Clinicopathological features of 9 cases of colorectal medullary carcinoma [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(03): 248-252.
[11]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[12]	Wenbo Niu, Fengpeng Wu, Yueping Liu, Chaoxi Zhou, Juan Zhang, Xuhua Hu, Baokun Li, Gueying Wang. Neoadjuvant chemoradiotherapy for treatment of locally advanced rectal cancer: Efficacy and tumor immune microenvironment changes [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 519-523.
[13]	Gaocai Mao, Jianbo Zhang, Yifang Yuan, Xiaobo Mao, Huiyong Dai, Zhe Wang. Diagnostic characteristics of clear cell type oxyphilic adenoma of salivary gland in retroauricular lymph nodes [J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(04): 261-265.
[14]	Ying Liu, Man Yin, Linqing Yang, Yunfei Wang. Diagnostic characteristics of invasive stratified mucin-producing carcinoma and literature review [J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(03): 173-177.
[15]	Xiaoyun Lu, Shuhan Yu, Zeyu Wu, Qide Zhang, Peiyao Wu. Expression and clinical significance of CCR2, CCL2 and Foxp3 in colon cancer [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2023, 10(01): 52-56.

Please choose a citation manager

Content to export